for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Co-Diagnostics Inc

CODX.OQ

Latest Trade

1.09USD

Change

0.01(+0.93%)

Volume

4,330

Today's Range

1.07

 - 

1.09

52 Week Range

0.70

 - 

3.77

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Co-Diagnostics Reports JV In India Has Been Notified That Regulatory Approval Is Imminent

Nov 13 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS, INC. REPORTS CONTINUED SALES MOMENTUM FOR Q3 2019.CO-DIAGNOSTICS INC - JV IN INDIA HAS BEEN NOTIFIED THAT REGULATORY APPROVAL IS IMMINENT.CO-DIAGNOSTICS INC - EXPECTS A SIGNIFICANT INCREASE DURING CURRENT QUARTER IN INFECTIOUS DISEASE TEST SALES.

Co-Diagnostics Launches Test To Identify Presence Of Zika, Dengue, Chikungunya

Oct 10 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS - ANNOUNCED PRODUCT LAUNCH OF VECTOR SMART ZDC TEST, USED TO IDENTIFY PRESENCE OF ZIKA, DENGUE, CHIKUNGUNYA IN MOSQUITO POPULATIONS.

Co-Diagnostics Inc Launches North American Mosquito Diagnostic Product

July 11 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS, INC. LAUNCHES NORTH AMERICAN MOSQUITO DIAGNOSTIC PRODUCT.CO-DIAGNOSTICS INC - PRODUCT LAUNCH OF THEIR VECTOR SMART NAM TEST.

Co-Diagnostics Says All Debt Incurred In 2018 Was Eliminated In Sale Of $3 Mln Of Preferred Shares In January 2019

April 2 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS, INC. REPORTS 2018 YEAR-END FINANCIAL RESULTS AND PROGRESS UPDATES.CO-DIAGNOSTICS - ALL DEBT INCURRED IN 2018 WAS ELIMINATED IN SALE OF $3 MILLION OF PREFERRED SHARES IN JANUARY 2019.

CVI Investments Reports A Passive Stake Of 7.8 Pct In Co-Diagnostics As Of Jan 31, 2019

Feb 11 (Reuters) - Co-Diagnostics Inc <CODX.O>::CVI INVESTMENTS REPORTS A PASSIVE STAKE OF 7.8 PERCENT IN CO-DIAGNOSTICS INC AS OF JAN 31, 2019 - SEC FILING.

Co-Diagnostics Announces Elimination Of Debt, Additional Capital Infusion

Jan 30 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS, INC. ANNOUNCES ELIMINATION OF DEBT, ADDITIONAL CAPITAL INFUSION.CO-DIAGNOSTICS INC - SALE OF $3 MILLION OF PREFERRED SHARES, CONVERTIBLE TO COMMON STOCK AT A FIXED PRICE OF $1.20 PER SHARE.CO-DIAGNOSTICS INC - TRANSACTION CONSISTED OF NEGOTIATING CONVERSION OF A $2 MILLION NOTE TO PREFERRED STOCK.CO-DIAGNOSTICS INC - TRANSACTION INCLUDED $3 MILLION OF PREFERRED SHARES, AND ELIMINATION OF $2 MILLION OF DEBT.

Co-Diagnostics Inc And LGC, Biosearch Technologies Sign License Agreement For Coprimer Technology

Oct 30 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS, INC. AND LGC, BIOSEARCH TECHNOLOGIES SIGN LICENSE AGREEMENT FOR COPRIMER TECHNOLOGY.CO-DIAGNOSTICS INC - CO-DIAGNOSTICS AGREES TO LICENSE COPRIMERS FOR USE IN AGRICULTURAL APPLICATIONS.

Co-Diagnostics Receives CE Mark For Zika Screening Test

Oct 18 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS, INC. RECEIVES CE MARK FOR ZIKA SCREENING TEST.CO-DIAGNOSTICS INC - CO'S LOGIX SMART ZIKA TEST TO BE AVAILABLE FOR PURCHASE WITH CE MARK.

Co-Diagnostics Files For Mixed Shelf Of Up To $25 Mln

Aug 14 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS INC FILES FOR MIXED SHELF OF UP TO $25 MILLION – SEC FILING.

Co-Diagnostics Receives CE Mark For Tuberculosis Test Kit

July 25 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS RECEIVES CE MARK FOR TUBERCULOSIS TEST KIT.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up